171 related articles for article (PubMed ID: 27839981)
21. Recombinant macrophage targeted enzyme replacement therapy for Gaucher disease in India.
Nagral A; Mewawalla P; Jagadeesh S; Kabra M; Phadke SR; Verma IC; Puri RD; Gupta N; Kishnani PS; Mistry PK
Indian Pediatr; 2011 Oct; 48(10):779-84. PubMed ID: 22080680
[TBL] [Abstract][Full Text] [Related]
22. The long-term international safety experience of imiglucerase therapy for Gaucher disease.
Starzyk K; Richards S; Yee J; Smith SE; Kingma W
Mol Genet Metab; 2007 Feb; 90(2):157-63. PubMed ID: 17079176
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage.
Giraldo P; Irún P; Alfonso P; Dalmau J; Fernández-Galán MA; Figueredo A; Hernández-Rivas JM; Julia A; Luño E; Marín-Jimenez F; Martín-Nuñez G; Montserrat JL; de la Serna J; Vidaller A; Villalón L; Pocovi M
Blood Cells Mol Dis; 2011 Jan; 46(1):115-8. PubMed ID: 20934891
[TBL] [Abstract][Full Text] [Related]
24. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1.
Kishnani PS; DiRocco M; Kaplan P; Mehta A; Pastores GM; Smith SE; Puga AC; Lemay RM; Weinreb NJ
Mol Genet Metab; 2009 Apr; 96(4):164-70. PubMed ID: 19195916
[TBL] [Abstract][Full Text] [Related]
25. [Current treatment for Gaucher's disease and new prospects].
Giraldo P; Latre P
Med Clin (Barc); 2011 Sep; 137 Suppl 1():50-4. PubMed ID: 22230127
[TBL] [Abstract][Full Text] [Related]
26. Management of Gaucher disease: enzyme replacement therapy.
Zimran A; Elstein D
Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():82-7. PubMed ID: 25345089
[TBL] [Abstract][Full Text] [Related]
27. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources.
Grabowski GA; Barton NW; Pastores G; Dambrosia JM; Banerjee TK; McKee MA; Parker C; Schiffmann R; Hill SC; Brady RO
Ann Intern Med; 1995 Jan; 122(1):33-9. PubMed ID: 7985893
[TBL] [Abstract][Full Text] [Related]
28. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement.
Elstein D; Dweck A; Attias D; Hadas-Halpern I; Zevin S; Altarescu G; Aerts JF; van Weely S; Zimran A
Blood; 2007 Oct; 110(7):2296-301. PubMed ID: 17609429
[TBL] [Abstract][Full Text] [Related]
29. Haemostatic abnormalities in treatment-naïve patients with Type 1 Gaucher's disease.
Mitrovic M; Antic D; Elezovic I; Janic D; Miljic P; Sumarac Z; Nikolic T; Suvajdzic N
Platelets; 2012; 23(2):143-9. PubMed ID: 21767238
[TBL] [Abstract][Full Text] [Related]
30. An evidence-based review of the potential benefits of taliglucerase alfa in the treatment of patients with Gaucher disease.
Hollak CE
Core Evid; 2012; 7():15-20. PubMed ID: 22654679
[TBL] [Abstract][Full Text] [Related]
31. Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults.
Mistry PK; Weinreb NJ; Kaplan P; Cole JA; Gwosdow AR; Hangartner T
Blood Cells Mol Dis; 2011 Jan; 46(1):66-72. PubMed ID: 21112800
[TBL] [Abstract][Full Text] [Related]
32. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment.
Pastores GM; Barnett NL; Kolodny EH
Clin Ther; 2005 Aug; 27(8):1215-27. PubMed ID: 16199246
[TBL] [Abstract][Full Text] [Related]
33. [Safety of use of velaglucerase in 2 patients with type 1 Gaucher's disease].
Latre P; Giraldo P
Med Clin (Barc); 2011 Sep; 137 Suppl 1():39-42. PubMed ID: 22230124
[TBL] [Abstract][Full Text] [Related]
34. Taliglucerase alfa approved for Gaucher disease.
Traynor K
Am J Health Syst Pharm; 2012 Jun; 69(12):1009. PubMed ID: 22644968
[No Abstract] [Full Text] [Related]
35. Outcome of pregnancies in women receiving velaglucerase alfa for Gaucher disease.
Elstein D; Hughes D; Goker-Alpan O; Stivel M; Baris HN; Cohen IJ; Granovsky-Grisaru S; Samueloff A; Mehta A; Zimran A
J Obstet Gynaecol Res; 2014 Apr; 40(4):968-75. PubMed ID: 24612151
[TBL] [Abstract][Full Text] [Related]
36. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
Wenstrup RJ; Kacena KA; Kaplan P; Pastores GM; Prakash-Cheng A; Zimran A; Hangartner TN
J Bone Miner Res; 2007 Jan; 22(1):119-26. PubMed ID: 17032149
[TBL] [Abstract][Full Text] [Related]
37. Low-dose low-frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher disease.
Elstein D; Abrahamov A; Hadas-Halpern I; Meyer A; Zimran A
QJM; 1998 Jul; 91(7):483-8. PubMed ID: 9797931
[TBL] [Abstract][Full Text] [Related]
38. Taliglucerase alfa for the treatment of Gaucher's disease.
Haddley K
Drugs Today (Barc); 2012 Aug; 48(8):525-32. PubMed ID: 22916340
[TBL] [Abstract][Full Text] [Related]
39. Minimal disease activity in Gaucher disease: criteria for definition.
Di Rocco M; Andria G; Bembi B; Carubbi F; Giona F; Giuffrida G; Linari S; Sibilio M; Spina V; Cappellini MD
Mol Genet Metab; 2012 Nov; 107(3):521-5. PubMed ID: 22954583
[TBL] [Abstract][Full Text] [Related]
40. Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years.
Hollak CE; Belmatoug N; Cole JA; Vom Dahl S; Deegan PB; Goldblatt J; Rosenbloom B; van Dussen L; Tylki-Szymańska A; Weinreb NJ; Zimran A; Cappellini MD
Br J Haematol; 2012 Aug; 158(4):528-38. PubMed ID: 22640238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
